HCV Treatment
AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down, according to presentations at the AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.
Coverage of IDWeek 2017
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego.
- Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
11/30/17
Web Design and Development by